LAG3 and renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions: Recent analyses by Bakouny et al. of the molecular and immune landscape of tRCC identified infiltration of unique CD8+ T-cell immunophenotypes that demonstrated increased LAG3 and decreased TIM-3 expression compared with ccRCC, indicating that LAG3-targeted immunotherapy may benefit these patients [80].